Hints and tips:
...It was a direct competitor to Tagamet, a big-selling drug produced by an American company, Smith Kline & French....
...Latham & Watkins has hired Rick Kline, Sarah Axtell and Navneeta Rekhi as partners in its corporate department....
...The company also named Deborah Waterhouse, chief executive of Glaxo-controlled ViiV Healthcare, to the board....
...For commentary on Hargreaves Lansdown’s dividend problem, Body Shop’s sale and Glaxo’s adjustments, see this morning’s Lombard column....
...Is Smith & Nephew the one that got away? The UK medical device maker has long been seen as a potential target for bigger US rivals....
...Beecham languished by comparison, later merging with Smith Kline and being subsequently subsumed within the GSK group....
...Believing that the science underlying beta blockers had other uses, he left ICI for the greater freedom offered by Smith Kline. Black’s hopes were realised....
...Smith & Nephew led Friday’s FTSE gainers, up 3.8 per cent to £10.65, on second-quarter sales and earnings that beat consensus estimates....
...From student days studying glaciers and urban agglomerations, Simon Dingemans now travels the world, guided by his spreadsheet in a search for improved returns for GlaxoSmith-Kline, the UK-based pharmaceutical...
...He started his career at French pharma group Roussel Uclaf and moved to Glaxo France in 1991....
...Simon Dingemans, one of Goldman Sachs’ veteran dealmakers in London, is leaving the bank to join drugmaker GlaxoSmith-Kline as chief financial officer at a time when global mergers and acquisitions activity...
...UK regulators have called for the withdrawal across Europe of GlaxoSmith-Kline’s diabetes drug Avandia, dealing a blow to the pharmaceuticals group in its home market....
...For investors seeking growth, Jonathan Jackson, head of equities at Killik & Co, prefers shares in Cobham, Smith & Nephew and Bovis Homes....
...So he left ICI for rival Smith Kline....
...Glaxo Smith Kline, BAT, Imperial Tobacco, and BT, for example, all offer prospective yields higher than 4.49per cent....
...The consensus was “underestimating the complexity of Advair’s device patents, over-crediting the competition and underestimating Advair’s international potential”, said Justin Smith, MF analyst....
...When he took charge of GlaxoSmithKline at the start of the decade, Jean-Pierre Garnier introduced a series of smaller “centres for excellence in drug discovery” focused on types of therapy....
...BAE Systems fell 5 per cent to 348½p and Smiths Group was down 4.8 per cent to 846½p....
...Glaxo was on a list of potential bidders for ImClone, the US biotech company. Smiths Group rose 3.7 per cent to £10.63, bouncing from a two-month low....
...The head of GlaxoSmith Kline, the British pharmaceutical group, has launched a robust defence of his consumer healthcare division in spite of investor pressure to sell some of its best-known brands amid...
...Mr Stout, who worked for Schering before joining GSK’s forerunner Smith Kline Beecham in 1996, was formally the boss of both Mr Witty and Mr Viehbacher, so his continued employment became more difficult...
...A few days later, instead of relaxing for the holidays, Mr Stéphenne, head of Smith Kline Biologicals, would be arguing for considerable investment from the full board of the parent company in the US, which...
...Dealers cited the latest mergers and acquisitions developments in the US, where Tishman Speyer, the owner of New York’s Chrysler Center, and Lehman Brothers, are paying $22.2bn for Archstone-Smith, the second...
...Kline & French, now much bigger (and better known) as GlaxoSmithKline....
International Edition